CA2271728A1 - Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux - Google Patents

Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux Download PDF

Info

Publication number
CA2271728A1
CA2271728A1 CA002271728A CA2271728A CA2271728A1 CA 2271728 A1 CA2271728 A1 CA 2271728A1 CA 002271728 A CA002271728 A CA 002271728A CA 2271728 A CA2271728 A CA 2271728A CA 2271728 A1 CA2271728 A1 CA 2271728A1
Authority
CA
Canada
Prior art keywords
methyl
carbon atoms
triazin
tetrahydro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271728A
Other languages
English (en)
Inventor
Robert John Steffan
Kevin Anthony Memoli
Donald Peter Strike
Amedeo Arturo Failli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2271728A1 publication Critical patent/CA2271728A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/08—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la structure de la formule générale (1) ou l'un de leurs sels pharmaceutiquement admis. Dans cette formule, R?1¿, R?2¿, R?3¿, R?4¿ et R?5¿ sont chacun indépendamment hydrogène, halogène, alkyl, cycloalkyl, phénylalkyl, alcoxy, aryloxy, fluoroalcoxy, trifluorométhyl, alkylthio, alkylsulfonyl, -SCF¿3?, nitro, alkylamino ou dialkylamino. R?6¿ est hydrogène, alkyl, cycloalkyl ou arylalkyl. Enfin, R?7¿ est alkyl, cycloalkyl, ou arylalkyl. Ces composés conviennent particulièrement comme agents anti-athéroscléreux.
CA002271728A 1996-11-14 1997-11-10 Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux Abandoned CA2271728A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74887696A 1996-11-14 1996-11-14
US08/748,876 1996-11-14
PCT/US1997/020233 WO1998021190A1 (fr) 1996-11-14 1997-11-10 Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux

Publications (1)

Publication Number Publication Date
CA2271728A1 true CA2271728A1 (fr) 1998-05-22

Family

ID=25011313

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271728A Abandoned CA2271728A1 (fr) 1996-11-14 1997-11-10 Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux

Country Status (7)

Country Link
EP (1) EP0938480A1 (fr)
JP (1) JP2001503769A (fr)
AR (1) AR010068A1 (fr)
AU (1) AU5170698A (fr)
CA (1) CA2271728A1 (fr)
WO (1) WO1998021190A1 (fr)
ZA (1) ZA9710265B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562814B2 (en) 2000-10-02 2003-05-13 Wyeth 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives
DE60203623T2 (de) * 2001-07-19 2006-01-19 CV Therapeutics, Inc., Palo Alto Substituierte piperazinderivate und ihre verwendung als fettsaüre-oxidationsinhibitoren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK236878A (da) * 1977-07-22 1979-01-23 Pfizer Tetrahydro-s-triazin-2(1h)-thioner
HUT62558A (en) * 1991-07-01 1993-05-28 Sandoz Ag Process for producing n-phenylthiourea derivaties and pharmaceutical compositions comprising same
US5554607A (en) * 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
EP0885197A1 (fr) * 1996-03-07 1998-12-23 American Home Products Corporation Derives de la 2-thioxotetrahydropyrimidin-4-one

Also Published As

Publication number Publication date
ZA9710265B (en) 1999-08-13
AR010068A1 (es) 2000-05-17
JP2001503769A (ja) 2001-03-21
AU5170698A (en) 1998-06-03
WO1998021190A1 (fr) 1998-05-22
EP0938480A1 (fr) 1999-09-01

Similar Documents

Publication Publication Date Title
US5554607A (en) Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
US5783707A (en) 2-thioxo-imidazolidin-4-one derivatives
US4760078A (en) Immunomodulator 1,2-dithiol-3-thione derivative composition, use method and process of producing the same
WO1997019931A1 (fr) Derives de 2-(substitution sulfanyle)-3,5-dihydroimidazol-4-one
US6160114A (en) Substituted tetrahydro-1,3,5-triazin-2[1H]-thiones as anti-atherosclerotic agents
JPS6041655A (ja) 尿素類およびチオ尿素類、それらの製造法並びに医薬用途
CA2271728A1 (fr) Tetrahydro-1,3,5-triazin-2[1h]-thiones substitues servant d'agents anti-atherosclereux
WO1998057928A1 (fr) Augmentation du taux du cholesterol des lphd par des 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
US6008362A (en) Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
WO1998057925A1 (fr) Augmentation du taux de cholesterol hdl par 2-[(aminothioxomethyl)hydrazono]-2-arylethyle carbamates
JPS59116288A (ja) ピラゾロ〔４．３−ｂ〕〔１．４〕オキサジン類
WO1997019932A1 (fr) Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite
US5210097A (en) Xanthocillin x monomethyl ether derivative and antitumor agent containing the same
US5807864A (en) 2-thioxo-tetrahydropyrimidin-4-one derivatives
US6049006A (en) Elevation of HDL cholesterol by N-[2-[(aminothioxomethyl) hydrazono]-2-arylethyl]amides
US6034272A (en) Elevation of HDL cholesterol by N-[4-[(aminothioxomethyl) hydrazono]-4-arylbutyl]amides
US4524147A (en) Uracil derivatives, process for preparing same, and pharmaceutical compositions comprising same
US5599829A (en) 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives for increasing HDL cholesterol levels
US5663363A (en) 2-thioxo-imidazolidin-4-one derivatives
US5821372A (en) 2-thioxo-imidazolidin-4-one derivatives
US5861517A (en) 2-thioxo-imidazolidin-4-one derivatives
US5939435A (en) 2-substituted-1-acyl-1,2-dihydroquinoline derivatives
US5877324A (en) 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
US6566375B1 (en) Elevation of HDL cholesterol by 4-[(aminothioxomethyl)-hydrazono]-N-(substituted)-4-arylbutanamides
US6011053A (en) Substituted indole-1-carbothioic acid amides as novel antiatherosclerotic agents

Legal Events

Date Code Title Description
FZDE Dead